Method for treating cancer
AssigneeEpizyme, Inc.
InventorHeike Keilhack
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.
Claims20
A method of inhibiting the ability of a cancer cell to induce immune dysfunction, comprising a step of contacting the cell with a therapeutically effective amount of an EZH2 inhibitor, wherein the cell (1) comprises aberrant, misregulated, or increased EZH2 activity;
- or (2) comprises a chromosomal translocation t(x;
- 18)(p11.2;q11.2) that causes a SS18-SSX fusion gene;
- or (3) has reduced function and/or expression of INI1.
A method of treating or alleviating symptoms of a disorder characterized by cancer-cell induced immune dysfunction in a subject comprising a step of administering to the subject a therapeutically effective amount of an EZH2 inhibitor;
- wherein the subject (1) comprises a chromosomal translocation t(x;
- 18) that causes a SS18-SSX fusion gene;
- or (2) has reduced function and/or expression of INTL.
Dependencies are inferred from the claim text.